Form 4: Foghorn Therapeutics CFO Acquires 120,000 Stock Options

Foghorn Therapeutics' Chief Financial Officer, Kristian Humer, has been granted 120,000 stock options, vesting over four years.

Summary

• Kristian Humer, the Chief Financial Officer of Foghorn Therapeutics, was granted 120,000 stock options on January 22, 2025.
• The exercise price of these options is $4.37 per share.
• The options vest over a four-year period, with 25% vesting on January 22, 2026, and the remaining 75% vesting quarterly thereafter.
• The options expire on January 21, 2035.

Sentiment

Score: 7

Explanation: The document reflects a routine executive compensation event, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term performance of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year followed by quarterly vesting is a typical structure for these types of grants.
• The exercise price of $4.37 is not directly comparable without knowing the current market price of the stock, but it is a common practice to set the exercise price at or near the market price at the time of the grant.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.

Key Dates

Keywords

stock options, Foghorn Therapeutics, insider trading, Kristian Humer, executive compensation, FHTX